Literature DB >> 11716544

Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation.

I Y De Potter1, Y Poumay, K A Squillace, M R Pittelkow.   

Abstract

Human EGF receptor (HER), also designated HER1, is an activatable tyrosine kinase receptor. HER1 activation regulates cell growth and differentiation in epidermal keratinocytes. Expression of other HER family members was investigated in human keratinocytes cultured under autocrine conditions. HER2 and HER3 are expressed and upregulated by confluence, concurrent with induction of epidermal differentiation. HER4 is not expressed by keratinocytes. Maximum expression of the cognate ligand, heregulin, is observed in subconfluent keratinocytes, and the expression of both heregulin alpha and beta isoforms is downregulated with confluence. Recombinant heregulin isoforms have no effect on colony formation and keratinocyte proliferation, but heregulin beta activates tyrosine phosphorylation of HER2 and HER3, with no effect on HER1, in confluent differentiating keratinocyte cultures. Also, heregulin beta increases HER2/HER3 heterodimerization under those conditions. Treatment of confluent cultures by heregulin beta correlates with cell signaling and inhibition of epidermal differentiation. Together, HER2, HER3, and heregulin constitute a potential autocrine-paracrine system involved in epidermal homeostasis and repair, as well as in hyperproliferative pathologies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716544     DOI: 10.1006/excr.2001.5390

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  19 in total

Review 1.  Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis.

Authors:  Cory L Simpson; Dipal M Patel; Kathleen J Green
Journal:  Nat Rev Mol Cell Biol       Date:  2011-08-23       Impact factor: 94.444

2.  Amphiregulin carboxy-terminal domain is required for autocrine keratinocyte growth.

Authors:  Stefan W Stoll; Jessica L Johnson; Yong Li; Laure Rittié; James T Elder
Journal:  J Invest Dermatol       Date:  2010-04-29       Impact factor: 8.551

3.  EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner.

Authors:  Andrew Johnston; Johann E Gudjonsson; Abhishek Aphale; Andrew M Guzman; Stefan W Stoll; James T Elder
Journal:  J Invest Dermatol       Date:  2010-10-21       Impact factor: 8.551

4.  Tufted hair folliculitis in a woman treated with trastuzumab.

Authors:  Ilana S Rosman; Milan J Anadkat
Journal:  Target Oncol       Date:  2010-10-15       Impact factor: 4.493

5.  Autocrine extracellular signal-regulated kinase (ERK) activation in normal human keratinocytes: metalloproteinase-mediated release of amphiregulin triggers signaling from ErbB1 to ERK.

Authors:  Sanjay Kansra; Stefan W Stoll; Jessica L Johnson; James T Elder
Journal:  Mol Biol Cell       Date:  2004-07-14       Impact factor: 4.138

6.  Metalloproteinase-mediated, context-dependent function of amphiregulin and HB-EGF in human keratinocytes and skin.

Authors:  Stefan W Stoll; Jessica L Johnson; Ajay Bhasin; Andrew Johnston; Johann E Gudjonsson; Laure Rittié; James T Elder
Journal:  J Invest Dermatol       Date:  2010-01       Impact factor: 8.551

7.  Psoriasis induced by trastuzumab (herceptin®).

Authors:  Dae Hun Kim; Nam Ji Jeong; Myung Im; Young Lee; Young Joon Seo; Jeung Hoon Lee
Journal:  Ann Dermatol       Date:  2013-05-10       Impact factor: 1.444

8.  Erbb2 suppresses DNA damage-induced checkpoint activation and UV-induced mouse skin tumorigenesis.

Authors:  Justin G Madson; David T Lynch; Jessica Svoboda; Rebecca Ophardt; Jodi Yanagida; Sumanth K Putta; Andrew Bowles; Carol S Trempus; Raymond W Tennant; Laura A Hansen
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

9.  Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.

Authors:  Douglas A Rubinson; Howard S Hochster; David P Ryan; Brian M Wolpin; Nadine Jackson McCleary; Thomas A Abrams; Jennifer A Chan; Syma Iqbal; Heinz J Lenz; Dean Lim; Jeffrey Rose; Tanios Bekaii-Saab; Helen X Chen; Charles S Fuchs; Kimmie Ng
Journal:  Invest New Drugs       Date:  2013-04-09       Impact factor: 3.850

10.  Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin.

Authors:  Laure Rittié; Sanjay Kansra; Stefan W Stoll; Yong Li; Johann E Gudjonsson; Yuan Shao; Lowell E Michael; Gary J Fisher; Timothy M Johnson; James T Elder
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.